Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities (2016 - 2018)

Fennec Pharmaceuticals filings provide 9 years of Other Non-Current Liabilities readings, the most recent being $167000.0 for Q2 2018.

  • On a quarterly basis, Other Non-Current Liabilities rose 206.37% to $167000.0 in Q2 2018 year-over-year; TTM through Jun 2018 was $167000.0, a 206.37% increase, with the full-year FY2017 number at $167000.0, up 406.06% from a year prior.
  • Other Non-Current Liabilities hit $167000.0 in Q2 2018 for Fennec Pharmaceuticals, roughly flat from $167000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.5 million in Q1 2014 to a low of -$157000.0 in Q2 2017.
  • Median Other Non-Current Liabilities over the past 5 years was $167000.0 (2017), compared with a mean of $1.2 million.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 2342.59% in 2014 and later crashed 97.34% in 2015.
  • Fennec Pharmaceuticals' Other Non-Current Liabilities stood at $1.3 million in 2014, then crashed by 93.78% to $82000.0 in 2015, then crashed by 59.76% to $33000.0 in 2016, then skyrocketed by 406.06% to $167000.0 in 2017, then changed by 0.0% to $167000.0 in 2018.
  • The last three reported values for Other Non-Current Liabilities were $167000.0 (Q2 2018), $167000.0 (Q4 2017), and -$157000.0 (Q2 2017) per Business Quant data.